Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
40–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of moderate-to-severe chronic obstructive pulmonary disease (COPD), as classified by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines and:
1. Smoking history of at least 20 pack-years.
2. Post-bronchodilator forced expiratory volume in 1 second (FEV1) \< 80% and ≥ 30% of the predicted normal value.
Patients who have been hospitalized for a COPD exacerbation in the 6 weeks prior to screening or during the 14 day run-in period prior to randomization.
Patients requiring long-term oxygen therapy (\> 15 hours a day) for chronic hypoxemia.
Patients who have had a respiratory tract infection within 6 weeks prior to screening.
Patients with concomitant pulmonary disease.
Patients with a history of asthma.
Patients with diabetes Type I or uncontrolled diabetes Type II.
Any patient with lung cancer or a history of lung cancer.
Any patient with active cancer or a history of cancer with less than 5 years disease-free survival time.
Patients with a history of long QT syndrome or whose QTc interval (Bazett's) measured at screening or randomization is prolonged.
Patients who have been vaccinated with live attenuated vaccines within 30 days prior to screening or during the run-in period.
Patients unable to successfully use a dry powder inhaler device or perform spirometry measurements.
Clareo Health | Confirmatory Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)
